Josh Wolfe is a co-founder and the managing partner at Lux Capital, a venture capital fund that invests in deep technology and frontier science. He serves on the boards of Aera Therapeutics, Cajal Neuroscience, Eikon Therapeutics, Impulse Labs, Kallyope, Osmo, and Variant Bio, and led investments in Anduril, Planet, Echodyne, Hadrian, and Resilience. A Westinghouse semi-finalist and published scientist, Josh began his career at Salomon Smith Barney and Merrill Lynch. He edits the Forbes/Wolfe...
Show more...